GS
NTLA icon

GTS Securities’s Intellia Therapeutics NTLA Stock Holding History

GTS Securities’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10,834
Closed -$139K – 1711
2026
Q1 		$139K Buy
+10,834
New +$138K ﹤0.01% 1410
2025
Q4 		– Sell
-23,109
Closed -$399K – 1673
2025
Q3 		$399K Buy
+23,109
New +$285K 0.02% 862

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

GTS Securities's NTLA Position: Q2 2026 in Review

GTS Securities sold out of Intellia Therapeutics (NTLA) in Q2 2026, closing a stake of 10,834 shares — an estimated $139K sold.

GTS Securities first reported a position in NTLA in Q3 2025 and held it in 2 quarters. The position peaked at $399K in Q3 2025. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • GTS Securities reported no remaining Intellia Therapeutics position as of Q2 2026 after selling out during the quarter.
  • GTS Securities sold 10,834 Intellia Therapeutics shares in Q2 2026, an estimated $139K.
  • GTS Securities first reported a position in Intellia Therapeutics in Q3 2025 and held it in 2 quarters.
  • GTS Securities's Intellia Therapeutics position peaked at $399K in Q3 2025.
  • 328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on GTS Securities's 13F filing for Q2 2026, filed 14 Aug 2026.